IL-36受体拮抗剂治疗泛发性脓疱型银屑病的机制及研究进展  

Mechanism and Progress of Interleukin-36 Receptor Antagonist in the Treatment of Generalized Pustular Psoriasis

作　　者：杨晶 肖异珠[1] 

机构地区：[1]重庆医科大学附属儿童医院皮肤科,国家儿童健康与疾病临床医学研究中心,儿童发育疾病研究教育部重点实验室,重庆

出　　处：《临床医学进展》2022年第5期4559-4564,共6页Advances in Clinical Medicine

摘　　要：泛发性脓疱型银屑病(Generalized Pustular Psoriasis, GPP)是一种感染、遗传及免疫等多因素介导的慢性炎症性皮肤病,其治疗困难,病情可迁延不愈,并合并多器官功能损害,对患者生理健康造成重大影响。近年来国内外发现IL36RN突变是GPP的主要致病基因,IL-36信号通路成为了其发病机制重要的一环,在此基础上提出并研究了IL-36受体拮抗剂对GPP的靶向药物治疗并取得了突破性进展Spesolimab (司柏索利)的产生。作为一种新的IL-36R单克隆抗体,通过阻断IL-36R信号通路达到治疗GPP的作用,进一步了解IL-36受体拮抗剂治疗机制及目前研究进展,对中国泛发性脓疱型银屑病患者有着重要临床意义。Generalized Pustular Psoriasis is a chronic inflammatory skin disease, mediated by many factors such as infection, heredity and immunity. It is difficult to be treated, has a significant impact on the patient’s physical health. In recent years, the mutation of IL36RN has been found to be the major pathogenic gene of GPP, and the IL-36 signal pathway has become an important link in the patho-genesis of GPP. On this basis, we proposed and studied the target drug therapy for GPP by IL-36 re-ceptor antagonist and made a breakthrough progress, Spesolimab. As a new biologics of IL-36R, it can interdict the signal pathway of IL-36R to treat GPP, as to further understand the mechanism of IL-36R antagonist therapy and the current research progress, has important clinical significance for Chinese patients with generalized pustular psoriasis.

关 键 词：泛发性脓疱型银屑病 IL-36受体拮抗剂 Spesolimab 生物制剂 

分 类 号：R758.63[医药卫生—皮肤病学与性病学]